Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831555 | 0.93 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL26985810 | 0.93 | KDM4E (0.70) | KDM4EALDH1A1SMN1; SMN2HRH3KCNH2 | |
| SCHEMBL10672014 | 0.88 | HRH3 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1HRH3 | |
| SCHEMBL11258963 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HRH3TSHR | |
| SCHEMBL13544385 | 0.83 | HRH3 (0.74) | KDM4EALDH1A1SMN1; SMN2L3MBTL1HRH3 | |
| SCHEMBL12323573 | 0.83 | KDM4E (0.86) | KDM4EALDH1A1SMN1; SMN2L3MBTL1HRH3 | |
| SCHEMBL4392386 | 0.82 | HRH3 (0.79) | HRH3 | |
| SCHEMBL30831619 | 0.82 | MEN1 (0.61) | KDM4EALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL26985925 | 0.82 | MEN1 (0.61) | KDM4EALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL6397785 | 0.82 | HRH3 (0.69) | KDM4EALDH1A1SMN1; SMN2L3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1727789-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | KDM4E 4348/4885ALDH1A1 102/4885SMN1; SMN2 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.